CentricsBio

본문 바로가기 주메뉴 바로가기

10 years of research for 100 years. A company of the endless challenge - CentricsBio: Innovative
Challenger
beyond
Immunotherapeutics

Business

Pipeline: Based on the cutting-edge technologies, we have been developing innovative new therapeutic antibody drugs that include combination therapies, immune cell therapies and autoimmune therapies.

CB301: This is CentricsBio's next-generation new antibody drug for the treatment of lung cancer and colon cancer.

CB201: New therapeutic design of Alzheimer's disease via activating immune cells in the brain.

CB302: We aim for enhanced anti-cancer effect with immune combination therapy.

CB303: We challenge a high therapeutic effect with the cell-specific therapeutic agents (CAR-T) specialized in solid cancer.

CB304: Providing a new paradigm of patient-specific treatment using proprietary cancer diagnosis markers.

CB501: It is a new treatment that removes the side effects of existing autoimmune diseases and corrects the immune system.

Partnership

Business Strategy: CentricsBio is working with well-known global
pharmaceutical companies as well as domestic and
overseas research institutes. Based on outstanding
researchers and innovative technologies,
CentricsBio aims to lead the world market through
lavish investment and development of new drugs
corresponding to global trends.

Partnership

Network: CentricsBio is working with well-known global
pharmaceutical companies as well as domestic and
overseas research institutes. Based on outstanding
researchers and innovative technologies,
CentricsBio aims to lead the world market through
lavish investment and development of new drugs
corresponding to global trends.

Community

Contact

CentricsBio has already attracted many investments, and all employees are working diligently to launch a new blockbuster drug to become a global company.